Jasper Therapeutics Inc
Jasper Therapeutics Inc (JSPR) Covered Calls
As of September 17, 2026, JSPR has 3 covered call opportunities in the coming three months. Return ranges from 81.0 to 89.7% until expiration. Annualized return ranges from 154.4 to 985.9%. The nearest expiration is October 16, 2026. Maximum potential profit is $52.
Read more
Running JSPR covered calls helps you generate consistent income from Jasper Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Jasper Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best JSPR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if JSPR stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling JSPR covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Jasper Therapeutics Inc covered call is worth writing.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Income-focused investors, long-term JSPR holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling JSPR covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Jasper Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile90.87% Elevated
- Market cap (M$)21
- 52 weeks high-76.58%
- 52 weeks low96.88%
- Analyst recommendationStrong Buy
1.00 - Target price$9.00
1328.57% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-09
- P/E—
- Future P/E—
- EPS (ttm)-1.58
- EPS growth next 5 years39.61%
As of September 17, 2026
| 2026-10-16 | 30 | 1.00 | 72.41 | 0.05 | 0.35 | 47.00 | 81.03 | 985.92 | -8.62 | +0.59 | 350 | 0.30 |
| 2027-01-15 | 121 | 1.00 | 72.41 | 0.05 | 0.20 | 47.00 | 81.03 | 244.44 | -8.62 | +0.47 | 493 | 0.15 |
| 2027-04-16 | 212 | 1.00 | 72.41 | 0.10 | 0.25 | 52.00 | 89.66 | 154.36 | -17.24 | +0.56 | 751 | 0.15 |
As of September 17, 2026
Sell covered calls with the data behind you
Find the best JSPR covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→